50479-22-6

Basic information

• Product Name: Butanoic acid, 4-aMino-, 1,1-diMethylethyl ester
• Synonyms: Butanoic acid, 4-aMino-, 1,1-diMethylethyl ester;tert-Butyl 4-AMinobutanoate;4-Aminobutanoic acid tert-butyl ester;Tert-Butyl 4-aminobutyrate
• CAS NO: 50479-22-6
• Molecular Formula: C₈H₁₇NO₂
• Molecular Weight: 159.22608
• Mol File: 50479-22-6.mol
• Article Data: 24

Chemical Properties

• Boiling Point: 210.9±23.0 °C(Predicted)
• Appearance: /
• Density: 0.948±0.06 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• PKA: 9.67±0.10(Predicted)
• CAS DataBase Reference: Butanoic acid, 4-aMino-, 1,1-diMethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Butanoic acid, 4-aMino-, 1,1-diMethylethyl ester(50479-22-6)
• EPA Substance Registry System: Butanoic acid, 4-aMino-, 1,1-diMethylethyl ester(50479-22-6)

Safety Data

• Hazardous Substances Data: 50479-22-6(Hazardous Substances Data)

Usage

General Description

Butanoic acid, 4-amino-, 1,1-dimethylethyl ester, also known as pivaloyloxymethyl butyrate, is a chemical compound used primarily as a prodrug form of butanoic acid. It is commonly utilized in pharmaceuticals to increase the bioavailability and efficacy of drugs by stabilizing and protecting the active ingredient. Butanoic acid, 4-amino-, 1,1-dimethylethyl ester is rapidly hydrolyzed in the body to release the active butanoic acid, which has anti-inflammatory and immunosuppressive properties. Pivaloyloxymethyl butyrate is also being researched for its potential use in treating various inflammatory and autoimmune conditions, and it shows promise as a therapeutic agent for conditions such as ulcerative colitis, Crohn's disease, and rheumatoid arthritis. However, further studies are needed to fully understand its mechanisms and potential applications in the medical field.

Upstream product

• 76197-90-5 tert-butyl 4-isocyanatobutanoate 
• 115-11-7 isobutene 
• 56-12-2 4-amino-n-butyric acid 
• 5105-79-3 4-(((benzyloxy)carbonyl)amino)butyric acid tert-butyl ester 

Downstream Products

• 5105-80-6 N--γ-L-glutaminyl-γ-Aminobuttersaeure-tert-butylester 
• 120686-27-3 (E)-3-(3-tert-Butoxycarbonyl-propylcarbamoyl)-4-phenyl-but-3-enoic acid ethyl ester 
• 114645-10-2 tert-butyl 4-benzamidobutanoate 
• 114645-04-4 4-(Acetyl-benzoyloxy-amino)-butyric acid tert-butyl ester 
• 174799-86-1 4-(Benzyl-benzyloxycarbonylmethyl-amino)-butyric acid tert-butyl ester 
• 174799-84-9 tert-butyl 4-(benzylamino)butanoate 
• 5105-94-2 N-(Benzyloxycarbonyl-α-L-glutamyl)-γ-aminobuttersaeure-tert.-butylester 
• 5105-92-0 N^α-Benzyloxycarbonyl-N^γ-(3-tert.-butoxycarbonyl-propyl)-L-glutaminsaeure-benzylester 

Relevant articles and documents

Switchable supramolecular organization of structurally defined micelles based on an amphiphilic fullerene

(Figure Presented) Exactly eight amphiphilic fullerene dendrimer molecules form a globular micelle spontaneously in aqueous solution. This supramolecular organization can be turned on and off by an external stimulus (pH). Owing to the remarkable structure persistence of the micelles, their three-dimensional structure could be determined from cryogenic transmission electron micrographic images and the molecular architecture was subsequently modeled (see picture).

CONJUGATION LINKERS CONTAINING 2,3-DIAMINOSUCCINYL GROUP

Provided is a conjugate of a cytotoxic drug/molecule to a cell-binding molecule with a bis-linker (adual-linker) containing a 2, 3-diaminosuccinyl group. It also relates to preparation of the conjugate of a cytotoxic drug/molecule to a cell-binding molecule with the bis-linker, particularly when the drug having functional groups of amino, hydroxyl, diamino, amino-hydroxyl, dihydroxyl, carboxyl, hydrazine, aldehyde and thiol for conjugation with the bis-linker in a specific manner, as well as the therapeutic use of the conjugates.

A CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS

The present invention relates to the conjugation of a tubulysin analog compound to a cell-binding molecule with branched/side-chain linkers for having better delivery of the conjugate compound and targeted treatment of abnormal cells. It also relates to a branched-linkage method of conjugation of a tubulysin analog molecule to a cell-binding ligand, as well as methods of using the conjugate in targeted treatment of cancer, infection and autoimmune disease.